First patent issued in Europe for Orexo's adrenaline product OX640

Corporate Breaking News

Home : First patent issued in Europe for Orexo's adrenaline product OX640

Sep 01 2022	First patent issued in Europe for Orexo's adrenaline product OX640
UPPSALA, Sweden, Sept. 1, 2022 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces that the European Patent Office (EPO) has granted the first European patent specifically relating to OX640, Orexo's nasal adrenaline rescue medication based on the amorphOX® drug...


Source:https://www.prnewswire.com:443/news-releases/first-patent-issued-in-europe-for-orexos-adrenaline-product-ox640-301616151.html

Related News
» Novem Group Named to 2022 Greater Rochester Chamber Top 100 » Yili Achieves Double-digit Revenue and Profit Growth in H1 FY2022